The European Consensus Development Conference 2002: Sex steroids and cardiovascular diseases: On the route to combined evidence from OC and HRT/ERT

Maturitas

Volumn 44, Issue 1, 2003, Pages 69-82

  Skouby, Sven O ^a   Jespersen, Jørgen ^e   Kluft, Cornelis ^b   Lowe, Gordon D O ^e   Norris, Lucy ^e   Stevenson, John ^c   Samsioe, Göran ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TNO   (Netherlands)

^c ST MARY S HOSPITAL   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e NONE

Author keywords

Adipositas; Animal model; Bio markers; Blood pressure; Cardiovascular diseases; Consensus development; Epidemiology; Estrogen; Glucose; Hemostasis; Hormone replacement therapy; Inflammation; Lipid; Oral contraceptives; Progestin; Risk factors; Thrombosis; Vessel wall

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CONJUGATED ESTROGEN; DIENOGEST; DROSPIRENONE; ELCOMETRINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FATTY ACID BINDING PROTEIN; GESTAGEN; GLUCOSE; LEPTIN; LEVONORGESTREL; LIPID; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NOMEGESTROL ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEX HORMONE; TRIMEGESTONE;

ACUTE HEART INFARCTION; ANAMNESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE PREDISPOSITION; ESTROGEN THERAPY; FOLLOW UP; GLUCOSE METABOLISM; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MASS SCREENING; NONHUMAN; OBESITY; ORGANIZATION; RANDOMIZATION; SOCIOECONOMICS; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VASODILATATION; VEIN THROMBOSIS;

ANIMALIA;

EID: 0037472858     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00351-1     Document Type: Conference Paper

References (6)

1. Olsen C.M. Consensus statements. Applying structure. J. Am. Med. Assoc. 273:1995;72-73.
2. Consensus Development Meeting: Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am. J. Obstet. Gynecol. 1990;162:1335-7.
3. Consensus Development Meeting: Combined oral contraceptives and cardiovascular diseases. Gynecol Endocrinol, 1996;10:1-5.
4. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;805-813.
5. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., et al. Cardiovascular disease outcome during 6.8 years of hormone therapy: heart and estrogen-progestin replacement study follow-up (HERS II). J. Am. Med. Assoc. 288:2002;49-57.
6. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. J. Am. Med. Assoc. 288:2002;321-333.